[go: up one dir, main page]

DE69916302D1 - USE OF DENDRITIC CELL-DEPLETED COMPOSITIONS TO IMPROVE THE TRANSPLANTATION OF ALLOGENIC HEMATOPOIETIC CELLS - Google Patents

USE OF DENDRITIC CELL-DEPLETED COMPOSITIONS TO IMPROVE THE TRANSPLANTATION OF ALLOGENIC HEMATOPOIETIC CELLS

Info

Publication number
DE69916302D1
DE69916302D1 DE69916302T DE69916302T DE69916302D1 DE 69916302 D1 DE69916302 D1 DE 69916302D1 DE 69916302 T DE69916302 T DE 69916302T DE 69916302 T DE69916302 T DE 69916302T DE 69916302 D1 DE69916302 D1 DE 69916302D1
Authority
DE
Germany
Prior art keywords
cells
hematopoietic system
transplantation
recipient
dendritic cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69916302T
Other languages
German (de)
Other versions
DE69916302T2 (en
Inventor
K Waller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Application granted granted Critical
Publication of DE69916302D1 publication Critical patent/DE69916302D1/en
Publication of DE69916302T2 publication Critical patent/DE69916302T2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

Methods of reducing or preventing graft versus host disease in an allogeneic hematopoietic system reconstituting cells transplant recipient comprising administering to the recipient allogeneic hematopoietic system reconstituting cells in which the number of dendritic cells has been effectively reduced, thereby reducing or preventing graft versus host disease, are provided. Also provided are methods of increasing the chance of survival for an allogeneic hematopoietic system reconstituting cells transplant recipient comprising administering to the recipient allogeneic hematopoietic system reconstituting cells in which the number of dendritic cells has been effectively reduced, thereby improving the chance for survival of the recipient. Columns for preparing hematopoietic system reconstituting cells prior to their transplantation are disclosed that provide for the selection of CD34+ cells and the removal of dendritic cell progenitors.
DE69916302T 1998-11-11 1999-11-10 USE OF DENDRITIC CELL-DEPLETED COMPOSITIONS TO IMPROVE THE TRANSPLANTATION OF ALLOGENIC HEMATOPOIETIC CELLS Expired - Fee Related DE69916302T2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US189577 1994-01-31
US18957798A 1998-11-11 1998-11-11
PCT/US1999/026773 WO2000027998A2 (en) 1998-11-11 1999-11-10 Method and compositions for improving allogeneic hematopoietic cell transplantation

Publications (2)

Publication Number Publication Date
DE69916302D1 true DE69916302D1 (en) 2004-05-13
DE69916302T2 DE69916302T2 (en) 2005-05-04

Family

ID=22697926

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69916302T Expired - Fee Related DE69916302T2 (en) 1998-11-11 1999-11-10 USE OF DENDRITIC CELL-DEPLETED COMPOSITIONS TO IMPROVE THE TRANSPLANTATION OF ALLOGENIC HEMATOPOIETIC CELLS

Country Status (9)

Country Link
EP (1) EP1123384B1 (en)
JP (1) JP2002529476A (en)
KR (1) KR20010090008A (en)
CN (1) CN1213143C (en)
AT (1) ATE263833T1 (en)
AU (1) AU779039B2 (en)
CA (1) CA2351194A1 (en)
DE (1) DE69916302T2 (en)
WO (1) WO2000027998A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2698091C (en) * 2007-08-31 2018-07-03 Brett Chevalier Wnt pathway stimulation in reprogramming somatic cells
CA2823782C (en) * 2011-01-10 2019-05-07 Samuel Strober Enhancement of allogeneic hematopoietic stem cell transplantation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5409813A (en) * 1993-09-30 1995-04-25 Systemix, Inc. Method for mammalian cell separation from a mixture of cell populations

Also Published As

Publication number Publication date
EP1123384A2 (en) 2001-08-16
JP2002529476A (en) 2002-09-10
CN1333688A (en) 2002-01-30
AU779039B2 (en) 2005-01-06
EP1123384B1 (en) 2004-04-07
CN1213143C (en) 2005-08-03
CA2351194A1 (en) 2000-05-18
WO2000027998A3 (en) 2000-07-27
ATE263833T1 (en) 2004-04-15
DE69916302T2 (en) 2005-05-04
AU1817800A (en) 2000-05-29
WO2000027998A2 (en) 2000-05-18
KR20010090008A (en) 2001-10-17

Similar Documents

Publication Publication Date Title
JP2002517227A5 (en) Methods and compositions for maintaining hematopoietic stem cells in vitro
Yañez et al. Adipose tissue‐derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft‐versus‐host disease
EP2048228B8 (en) Human liver progenitors
GB2392674A (en) Mesenchymal cells and osteoblasts from human embryonic stem cell
SG152273A1 (en) Pdx1 expressing endoderm
PT1379671E (en) Methods to culture circovirus
WO2003012060A3 (en) Cellular compositions which facilitate engraftment of hematopoietic stem cells while minimizing the risk of gvhd
EP1077599A4 (en) PARTICLE BOMBARDMENT TRANSFORMATION OF $i(BRASSICA)
DE69634982D1 (en) PROCESS FOR INCREASING HEMATOPOIETIC CELLS
DK0952772T3 (en) Methods of using mononuclear phagocytes to promote axonal regeneration
WO2006047743A3 (en) Swine multipotent adult progenitor cells
BR9612821A (en) Methods for preventing graft rejection in transplantation and for producing a host cell for universal gene therapy
ATE335808T1 (en) PREPARATION OF CELL SUSPENSIONS
WO2009035612A3 (en) Multilineage-inducible cells and uses thereof
WO2002017935A3 (en) A method of transplantation using chemotherapy-treated allogeneic cells that enhance immune responses without graft versus host disease
WO2005017115A3 (en) Cord blood-derived hematopoietic progenitor cells
DE69916302D1 (en) USE OF DENDRITIC CELL-DEPLETED COMPOSITIONS TO IMPROVE THE TRANSPLANTATION OF ALLOGENIC HEMATOPOIETIC CELLS
DE69737455D1 (en) DEFINED SYSTEMS FOR CULTIVATING EPITHELIAL CELLS AND USE THEREOF
Jazbec et al. Chimerism and gene therapy—Lessons learned from non‐conditioned murine bone marrow transplantation models
WO2005032463A3 (en) Educated nkt cells and their uses in the treatment of immune-related disorders
WO2003029432A3 (en) Human mesenchymal progenitor cell
Ji et al. Genome editing HLA alleles for a pilot immunocompatible hESC line in a Chinese hESC bank for cell therapies
PT765398E (en) POPULATION OF ENRICHING CELLS IN MYELOID AND LYMPHOID PROGENITORS AND METHODS OF MAKING AND USING
DE69528473D1 (en) USE OF HEPATOCYTE GROWTH FACTOR FOR INDUCING PROLIFERATION AND DIFFERENTIATION OF HEMATOPOIETIC CELLS
DK1140149T3 (en) Use of Human Growth Hormone to Increase the Number of Circulating CD34 + Cells Intended to Restore the Hematopoietic System and Immune System Following Myeloablative or Antibalstic Therapies in Transplant ......

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee